Biocept has partnered with Quest Diagnostics to offer its Target Selector next-generation sequencing (NGS)-based liquid biopsy targeted lung cancer panel to the latter’s customers.
The less invasive, lab-developed assay is used to perform genomic profiling in advanced non-small cell lung cancer (NSCLC) patients for facilitating advanced targeted treatments and analysing the therapy’s effectiveness.
The panel has the most common clinically actionable genes for NSCLC. It merges Biocept’s liquid biopsy biomarker testing capabilities with NGS and decision support resources.
Nearly 70% of the biomarkers analysed by the targeted and actionable NGS solution are as per the National Comprehensive Cancer Center guidance and/or US Food and Drug Administration-approved treatments.
Biocept president and CEO Michael Nall said: “We are pleased to expand Biocept’s relationship with Quest Diagnostics, as we believe its expertise and reach will allow us to serve more patients and potentially grow our customer base.”
Biocept and Quest intend to make these lab testing services available for the latter’s providers and patients in the fourth quarter of the year.
With doctors’ instructions, patients will be able to provide blood samples for testing at any of the 2,200 Quest patient service centres in the US.
Quest Diagnostics oncology franchise general manager Kristie Dolan said: “Lung cancer is one of the most prevalent and deadliest cancers.
“Better tools to aid in therapy selection and monitoring are urgently needed to improve patient outcomes, which is why we are so excited to work with Biocept on this focused test.
“Quest has the national scale, oncology expertise and network provider relationships to broaden access to this important innovation in order to potentially improve care for patients in treatment for lung cancer.”
Last month, Quest partnered with Paige to develop software products leveraging artificial intelligence to enhance and expedite the pathologic diagnoses of cancer and various other diseases.